{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/conjunctivitis-allergic/management/management-in-primary-care/","result":{"pageContext":{"chapter":{"id":"77a507ec-4dff-5204-b375-121264b0adf8","slug":"management-in-primary-care","fullItemName":"Scenario: Management in primary care","depth":2,"htmlHeader":"<!-- begin field d1339da6-a5a0-4895-8f64-b6665865d972 --><h2>Scenario: Management in primary care</h2><!-- end field d1339da6-a5a0-4895-8f64-b6665865d972 -->","summary":"Covers the management of allergic conjunctivitis in primary care.","htmlStringContent":"<!-- begin item c13d2829-9241-4399-b4af-fb26f4ff9ecc --><!-- begin field a82b26b8-cd6a-4c67-a4b2-acbc0156d21c --><p>From age 1 month onwards.</p><!-- end field a82b26b8-cd6a-4c67-a4b2-acbc0156d21c --><!-- end item c13d2829-9241-4399-b4af-fb26f4ff9ecc -->","topic":{"id":"b4698c45-6b7c-5244-836f-430591327957","topicId":"27f540e5-bb8e-4cee-a0aa-be515efa4fc2","topicName":"Conjunctivitis - allergic","slug":"conjunctivitis-allergic","lastRevised":"Last revised in October 2020","chapters":[{"id":"bc756208-c2a7-5b33-a4cb-67c41a75ecb0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6470bf56-596c-5d66-b2b2-ba79590bb255","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"17755f2a-0980-50f9-b62e-a34968c9682e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b1dc6613-43b4-55fe-9216-a83aab0ef918","slug":"changes","fullItemName":"Changes"},{"id":"ba5e8d6b-90f7-5b69-b09a-2bb0c2692918","slug":"update","fullItemName":"Update"}]},{"id":"fee1ca82-9d2a-50a4-9230-1a93482b8b4f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3d036930-da50-5ea2-82e1-1d0fb936a8b4","slug":"goals","fullItemName":"Goals"},{"id":"9ba6a0ce-0eae-5442-85f0-81f7ff71345b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"48935dfe-bca1-53fa-8d50-fa978331bd56","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"35b962f0-ec6b-53c9-b6f2-a5783ae10716","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8e9984f4-8c0d-5231-9eec-91a9fb49ecc4","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8fa3b231-6e2b-5fa2-aa0c-eb5359ff8160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ebf46a5d-2a79-5df8-82dd-d23fcb0559f1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"67185462-9d0a-5b7d-b8af-80b8958f2420","slug":"definition","fullItemName":"Definition"},{"id":"1c320f1a-b91f-5d5b-a47b-dc0094518883","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b21baf96-f39b-5eeb-934b-c193a434933d","slug":"causes","fullItemName":"Causes"},{"id":"923b6415-5fe1-550a-baf5-89285f8ddf77","slug":"complications","fullItemName":"Complications"},{"id":"a679bff6-4749-539e-bdb0-a762a9f91728","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a7d99d63-f47f-54bf-a60f-8ae6f2a42fb9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"089d5cf7-0f6b-521b-88c1-d4f25eef7101","slug":"assessment","fullItemName":"Assessment"},{"id":"7bb8bdb4-0279-5783-ba21-e44e8bcd0832","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"9a95dbd6-aaa4-5d6a-aa5b-9635d279f9a0","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"51e7c1d5-cd3d-5dea-a8ec-5a38deb58245","fullItemName":"Management","slug":"management","subChapters":[{"id":"e4ced49a-4b06-5559-9efb-c708812a8065","slug":"referral","fullItemName":"Scenario: Referral"},{"id":"77a507ec-4dff-5204-b375-121264b0adf8","slug":"management-in-primary-care","fullItemName":"Scenario: Management in primary care"}]},{"id":"452bc42e-1fe8-56e6-8511-57362d05fe3f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f9e89c16-d4a7-5241-86f6-1f78eacc68fa","slug":"topical-ocular-antihistamines-mast-cell-stabilizers","fullItemName":"Topical ocular antihistamines and mast cell stabilizers"},{"id":"f9a1678c-7117-5852-af35-628b676780c8","slug":"mast-cell-stabilizers","fullItemName":"Mast cell stabilizers"}]},{"id":"a32b7db8-1764-58b8-adbb-ab8ce0f44e46","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bd1a2d20-e91f-51f1-a2a2-486ebf015f65","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bc4e76de-c203-5f3e-ad9a-b84d6bc9d81e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"565b3a01-b21e-5837-b9f1-49fda55982ad","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b08973ef-af46-5e6f-b85c-d0bd9ca40bab","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3003e52e-8597-505e-a3ce-e46fde4c0c20","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"b7947929-e2f9-50c7-b5cd-3e34b802bae1","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3819cbbb-ca8c-58b7-b608-0a9567c5d5b5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"51e7c1d5-cd3d-5dea-a8ec-5a38deb58245","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"05d14718-2554-5754-a025-1747c2546cea","slug":"management-in-primary-care","fullItemName":"Management in primary care","depth":3,"htmlHeader":"<!-- begin field 49a5bb48-288d-4706-8268-80afbfffea40 --><h3>How do I manage a person with allergic conjunctivitis in primary care?</h3><!-- end field 49a5bb48-288d-4706-8268-80afbfffea40 -->","summary":null,"htmlStringContent":"<!-- begin item 859b1151-d8c2-4612-8a82-8be64e4df69c --><!-- begin field 8c685c7b-e761-45af-93be-4f42e73904ab --><ul><li>If <a class=\"topic-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/management/referral/#who-should-i-refer\">referral to secondary care</a> is not required:<ul><li>Advise the person on non-pharmacological management including:<ul><li>Avoidance of allergens for example through dust mite, mould and animal dander control, avoidance of pets and proper ventilation of home and office environments. Washing the hair before going to bed may help reduce allergen exposure.</li><li>Avoidance of eye rubbing.</li><li>Application of cold compresses to the eyes (for 5–10 minutes once or twice daily) to relieve symptoms.</li><li>Application of ocular surface lubricants such as saline solution or artificial tears — certain products cannot be used with contact lenses and the manufacturer's literature on product characteristics should always be consulted prior to application.</li><li>Advise the person that after using eye drops or eye ointments, they should not drive or perform other skilled tasks until vision is clear.</li></ul></li><li>If non-pharmacological measures do not provide adequate relief:<ul><li>Consider prescribing a topical antihistamine or dual action mast cell stabilizer and topical antihistamine — certain products are not licenced in young children.</li><li>Some topical antihistamines are combined with a vasoconstrictor agent — chronic use of these products is associated with rebound vasodilation once the product is stopped.</li><li>Mast cell stabilizers can be used if symptoms are recurrent or persistent — advise the person that a long loading period is required and mast cell stabilizers need to be applied routinely for several weeks to provide prophylactic benefit.</li><li>Advise the person that after using eye drops or eye ointments, they should not drive or perform other skilled tasks until vision is clear.</li><li>If the person is a contact lens wearer advise them that contact lens use should be avoided for the duration of topical treatment.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/prescribing-information/\">Prescribing</a> for further information.</li></ul></li><li>Provide patient information, for example:<ul><li>A patient information factsheet (<a data-hyperlink-id=\"cc5c9309-cbd0-43b4-91af-a95700dfb6d5\" href=\"http://www.allergyuk.org/downloads/factsheets/types-of-allergy/allergic-eye-disease.pdf\" target=\"_blank\">Allergic eye disease</a>) from Allergy UK (<a data-hyperlink-id=\"fb6acf70-a407-4292-948d-a95700dfb6f1\" href=\"http://www.allergyuk.org/\" target=\"_blank\">www.allergyuk.org</a>).</li><li>Online information (<a data-hyperlink-id=\"5f81dbbe-f78d-4d0b-a3f8-a95700dfb716\" href=\"https://www.nhs.uk/conditions/conjunctivitis/\">Conjunctivitis</a>) available from the NHS (<a data-hyperlink-id=\"522233f9-0b12-4f83-88f9-a95700dfb720\" href=\"https://www.nhs.uk/conditions/\">www.nhs.uk</a>).</li></ul></li><li>Arrange review in 1 week to assess therapeutic response — safety net in the interim and ensure the patient is aware of <a class=\"topic-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/diagnosis/assessment/\">red flag symptoms</a> that indicate the need for urgent review.</li></ul></li></ul><!-- end field 8c685c7b-e761-45af-93be-4f42e73904ab --><!-- end item 859b1151-d8c2-4612-8a82-8be64e4df69c -->","subChapters":[{"id":"b9855168-0f36-5c2c-aeb2-2514be7f5a57","slug":"basis-for-recommendation-6bd","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 0c6adde8-bff8-4a69-a637-420c8a5574c2 --><h4>Basis for recommendation</h4><!-- end field 0c6adde8-bff8-4a69-a637-420c8a5574c2 -->","summary":null,"htmlStringContent":"<!-- begin item 6bd7e420-fa1a-4c76-b5f8-9a779661a728 --><!-- begin field f55b946e-ed9a-4a7d-86c6-5d706868788e --><p>The recommendations on the management of allergic conjunctivitis in primary care are based on the clinical guidelines <em>Clinical management guidelines: Conjunctivitis (acute allergic)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">College of Optometrists, 2015a</a>] and <em>Clinical management guidelines: seasonal allergic conjunctivitis (hay fever conjunctivitis); Perennial allergic conjunctivitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">College of Optometrists, 2015b</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Bielory, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Bilkhu, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Azari, 2013b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Bielory, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">O&#39;Brien, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Wong, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Abelson, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Alfonso, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Berger, 2017</a>].</p><h5>Non-pharmacological measures</h5><ul><li>Avoidance of eye rubbing — eye rubbing causes mast cell degranulation and may self-inoculate the eye with allergen [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Berger, 2017</a>].</li><li>Artificial tears, lubricant eye drops and saline solution irrigate the eye, dilute and remove antigens, form a barrier and soothe the ocular surface — this may provide adequate relief in mild ocular allergy but does not treat the underlying allergic response or modify inflammatory mediators [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Bielory, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Abelson, 2015</a>].</li></ul><h5>Pharmacological measures</h5><ul><li>The College of Optometrists advise that a variety of topical treatments are available for example, topical mast cell stabilizers (such as sodium cromoglicate), topical antihistamine (such as azelastine, emedastine or epinastine) and dual action topical antihistamine plus mast cell inhibitor (such as olopatadine or ketotifen) but there is insufficient evidence to recommend use of one over another [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">College of Optometrists, 2015b</a>].<ul><li>Topical antihistamines have been found to be more effective in alleviating ocular symptoms than systemic antihistamines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Abelson, 2015</a>].<ul><li>Topical antihistamines are applied directly to the ocular surface providing localized and more rapid relief than systemic antihistamines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Bielory, 2012</a>].</li><li>Systemic antihistamines may cause drying of the ocular surface and are not recommended for treatment of allergic conjunctivitis in people who do not have concurrent rhinitis or sinusitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Bielory, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Abelson, 2015</a>] — for further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/allergic-rhinitis/\">Allergic rhinitis</a>.</li><li>Additional side effects of systemic antihistamines include sedation and cardiotoxicity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Bielory, 2012</a>].</li></ul></li><li>Mast cell stabilizers<ul><li>Mast cell stabilizers prevent degranulation of mast cells and release of pre-formed inflammatory mediators — they require a long loading period and need to be applied routinely for several weeks to attain optimal prophylactic benefit [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Butrus, 2005</a>].</li><li>This potentially long lead time for therapuetic benefit is likely to decrease patient compliance and expert opinion in a review article suggests that for this reason they are rarely used in isolation as treatment for acute allergic conjunctivitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Bielory, 2013</a>].</li></ul></li><li>Combination topical antihistamine and mast cell stabilizers such as olopatadine and ketotifen provide relief of symptoms through inhibition of mast cell degranulation in addition to competitive binding of the H1 receptor blocking histamine binding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Bielory, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">BMJ Best Practice, 2017a</a>].<ul><li>A Cochrane review (n = 30 studies) found that topical antihistamines and mast cell stabilisers, alone or in combination, are safe and effective in reduction of symptoms of seasonal and perennial allergic conjunctivitis when compared to placebo in the short term. No long-term data on efficacy was identified and there was insufficient evidence on which topical antihistamines and mast cell stabilisers are most effective [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Castillo, 2015</a>].</li><li>Pooled estimates from 4 studies found that olopatadine may be more effective than ketotifen in improving ocular itching, but not tearing, after 14 days of treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">CADTH, 2016</a>].</li><li>A systematic review and meta-analysis found that olopatadine was inferior to alcaftadine in reducing ocular itch (p < 0.00001) but comparable with epinastine and ketotifen [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Kam, 2016</a>].</li><li>Expert opinion in a pharmacy update on antihistamine use in children is that olopatadine eye drops are superior to sodium cromoglicate, more cost effective and reduce general practitioner attendances [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Fitzsimons, 2015</a>].</li><li>As dual agents usually have a rapid onset of antihistamine action (within minutes following application) patient compliance is improved compared with use of mast cell stabilizers alone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Bielory, 2012</a>].</li></ul></li></ul></li></ul><!-- end field f55b946e-ed9a-4a7d-86c6-5d706868788e --><!-- end item 6bd7e420-fa1a-4c76-b5f8-9a779661a728 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}